News
Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
3d
Pharmaceutical Technology on MSNNovo Nordisk defeated in Wegovy patent dispute by ViatrisThe Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.
In a head-to-head study in the New England Journal of Medicine, people taking Zepbound, Wegovy, Zepbound led to greater weight loss.
Novo Nordisk, the maker of Wegovy, announced exclusively on "Good Morning America" Tuesday that the medication will soon be available for purchase through the telehealth companies Ro, Hims and ...
Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year later, according to an analysis of U.S. pharmacy claims.
As of May 22, manufacturers are no longer allowed to distribute the compounded versions of semaglutide, which Novo Nordisk sells under the brand Wegovy for weight loss and Ozempic for diabetes.
Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ending a collaboration with the telehealth company less than two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results